Search

Your search keyword '"Shinde, Shivani S."' showing total 15 results
Start Over Author "Shinde, Shivani S."
15 results on '"Shinde, Shivani S."'

9. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes

Author

Sharma, Prashant, primary, Shinde, Shivani S., additional, Damlaj, Moussab, additional, Hefazi Rorghabeh, Mehrdad, additional, Hashmi, Shahrukh K., additional, Litzow, Mark R., additional, Hogan, William J., additional, Gangat, Naseema, additional, Elliott, Michelle A., additional, Al-Kali, Aref, additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal M., additional

Published
2016
Full Text
View/download PDF

13. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.

Author

Sharma, Prashant, Shinde, Shivani S., Damlaj, Moussab, Hefazi Rorghabeh, Mehrdad, Hashmi, Shahrukh K., Litzow, Mark R., Hogan, William J., Gangat, Naseema, Elliott, Michelle A., Al-Kali, Aref, Tefferi, Ayalew, and Patnaik, Mrinal M.

Subjects
*HEMATOPOIETIC stem cell transplantation, *HEMATOPOIETIC stem cells, *MYELODYSPLASTIC syndromes, *SYNDROMES, *DRUG efficacy, *PATIENTS, *THERAPEUTICS
Abstract

MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasm) overlap syndromes are myeloid malignancies for which allogeneic hematopoietic stem cell transplant (allo-HSCT) is potentially curative. We describe transplant outcomes of 43 patients – 35 with chronic myelomonocytic leukemia, CMML (of which 17 had blast transformation, BT) and eight with MDS/MPN-unclassifiable (MDS/MPN,U). At median follow-up of 21 months, overall survival (OS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were 55%, 29%, and 25% respectively in CMML without BT and 47%, 40%, and 34% respectively in CMML with BT. Higher HSCT-comorbidity index (HSCT-CI >3 versus ≤3;p = 0.015) and splenomegaly (p = 0.006) predicted worse OS in CMML without BT. In CMML with BT, engraftment failure (p = 0.006) and higher HSCT-CI (p = 0.03) were associated with inferior OS, while HSCT within 1-year of diagnosis was associated with improved OS (p = 0.045). In MDS/MPN,U, at median follow-up of 15 months, OS, CIR, and NRM were 62%, 30%, and 14%, respectively. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results